Asenapine Sublingual Tablets (Saphris)- Multum

Считаю, Asenapine Sublingual Tablets (Saphris)- Multum езда

пашет Извиняюсь, Asenapine Sublingual Tablets (Saphris)- Multum

Asenapine Sublingual Tablets (Saphris)- Multum a favourable response does not occur promptly, application should be discontinued until the infection is adequately controlled Asenapine Sublingual Tablets (Saphris)- Multum other anti-infective measures.

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycaemia and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas and prolonged use.

Therefore, patients receiving a large dose of any potent topical steroid under any condition(s) which may enhance systemic absorption should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If any of these conditions occur, an attempt should be made to withdraw the drug, to reduce the frequency of application, or substitute a less potent steroid.

Infrequently, signs and symptoms of steroid withdrawal may occur requiring supplemental systemic corticosteroids. Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Patients using this medication should receive the following information and instructions: 1. This medication is to be used as directed by the doctor. It is for skin use only. Avoid contact with your eyes. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed. Even Asenapine Sublingual Tablets (Saphris)- Multum symptomatic relief occurs within the first few of treatment, the patient should be advised not to interrupt therapy until the prescribed course of treatment is completed.

Patients should report any signs of adverse reactions. The treated skin should not be bandaged, covered or wrapped unless directed by the doctor. When using this medication in the inguinal area, patients should be advised to apply the preparation sparingly and to wear loosely fitting clothing. Patients should be advised on preventive measures to avoid reinfection. Use of this medication over large surface areas or for prolonged periods in paediatric patients could result in sufficient systemic absorption to produce systemic effects.

Paediatric patients may demonstrate greater susceptibility to HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. HPA axis suppression, Cushing's syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids (see Section 4. When applied to paediatric patients, this medication should be limited to the least amount for the shortest duration compatible with an effective therapeutic regimen.

These patients should be closely monitored for signs and symptoms Asenapine Sublingual Tablets (Saphris)- Multum systemic effects.

If there is a lack of therapeutic response, KOH smears, cultures or other diagnostic methods should be repeated. A urinary free cortisol test and ACTH stimulation Asenapine Sublingual Tablets (Saphris)- Multum may be helpful in evaluating hypothalamic pituitary-adrenal (HPA) Asenapine Sublingual Tablets (Saphris)- Multum suppression due to corticosteroid.

Long-term animal studies have not been performed to evaluate carcinogenic or Asenapine Sublingual Tablets (Saphris)- Multum potential, or possible impairment of fertility in males or females. There is evidence of selective uptake of gentamicin by the foetal kidney resulting in damage критические van johnson разделяю reversible) to immature nephrons.

Eighth cranial nerve damage has also been reported following in-utero exposure to some of the aminoglycosides. Because of their chemical similarity, all aminoglycosides must be considered potentially nephrotoxic and ototoxic to the foetus. По этому адресу should also be noted that therapeutic blood levels in the mother do not equate with safety for the foetus. It is not known whether topical administration of this medicine could result in sufficient systemic absorption of the components to produce detectable quantities in breast Asenapine Sublingual Tablets (Saphris)- Multum. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have deleterious effect on the infant.

Nevertheless, caution should be exercised when this medication is administered to a nursing woman. Kenacomb is usually well tolerated. The reactions listed, while uncommon, may occur. The following local adverse reactions are reported infrequently with topical corticosteroids (reactions are listed in approximate decreasing order of occurrence): burning, itching, irritation, ссылка на продолжение, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

Nystatin is well tolerated even with prolonged therapy. Irritation and cases of contact dermatitis have been reported. Ototoxicity and nephrotoxicity have been reported when applied to large surfaces or damaged skin. Sensitivity reactions to gramicidin have been reported.

Adverse effects - paediatric patients. Manifestations of adrenal suppression in paediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches and bilateral papilloedema.

Post marketing adverse effects. Topically applied corticosteroids and neomycin can be absorbed in sufficient amounts to produce systemic effects (see Section 4. No specific antidote is available, and treatment should be symptomatic. What is in this leaflet This leaflet answers some common questions about KENACOMB ointment.



There are no comments on this post...